CCRC - Certified Clinical Research Coordinator Product Development & Regulation Questions and Answers

Question 1

A sponsor has successfully completed a Phase I trial for a new oncology drug, establishing its initial safety profile and identifying a maximum tolerated dose in healthy volunteers.
What is the primary objective of the subsequent Phase II clinical trial?

Accepted Answer

To evaluate the drug's effectiveness for a specific cancer type in a well-defined patient group and to further assess its short-term safety and side effects.

Answer

To confirm the drug's efficacy and safety in a large, diverse patient population to support a New Drug Application (NDA).

Answer

To gather post-marketing data on the drug's long-term risks, benefits, and optimal use in the general patient population.

Answer

To determine the drug's metabolism, pharmacokinetic properties, and major toxicities for the first time in human subjects.

Question 2

Which of the following statements is most accurate regarding the Investigator's Brochure (IB)?

Accepted Answer

It is a comprehensive compilation of the clinical and nonclinical data on the investigational product known to date and is maintained by the sponsor.

Answer

It is created by the clinical research coordinator and is only updated upon completion of the study for the final report to the IRB.

Answer

It is a promotional document designed to highlight the potential benefits of the investigational product to recruit investigators.

Answer

It contains only the protocol and informed consent form for a specific clinical trial.

Question 3

A medical device company has developed a novel, implantable deep brain stimulation device for treating severe depression. This type of device is considered a significant risk. Before initiating a clinical trial to evaluate its safety and effectiveness, the sponsor must obtain which of the following from the FDA?

Accepted Answer

An Investigational Device Exemption (IDE).

Answer

A 510(k) premarket notification clearance.

Answer

A Premarket Approval (PMA).

Answer

A New Drug Application (NDA).

Question 4

During a Phase I trial for a new antiviral agent, several participants are hospitalized with acute liver failure, an unexpected and severe adverse reaction. The FDA orders the sponsor to immediately stop dosing all participants and halt new enrollment. This regulatory action is called a:

Accepted Answer

Clinical Hold

Answer

Protocol Deviation Report

Answer

Sponsor-Initiated Suspension

Answer

IRB Revocation of Approval

Question 5

Before a sponsor can legally ship an investigational new drug across state lines to a clinical investigator to begin a study in humans, the sponsor must first submit which application to the FDA?

Accepted Answer

An Investigational New Drug (IND) application

Answer

A Marketing Authorization Application (MAA)

Answer

A New Drug Application (NDA)

Answer

A Biologics License Application (BLA)

Question 6

By signing the FDA Form 1572, Statement of Investigator, a clinical investigator makes a binding commitment to the sponsor to perform which of the following actions?

Accepted Answer

Personally conduct or supervise the investigation and ensure that all study staff are informed about their obligations.

Answer

Submit the final study report and New Drug Application directly to the FDA.

Answer

Guarantee a minimum number of participants will be enrolled at the site.

Answer

Publish the study results in a peer-reviewed journal within one year of study completion.

A sponsor has successfully completed a Phase I trial for a new oncology drug, establishing its initial safety profile and identifying a maximum tolerated dose in healthy volunteers.What is the primary objective of the subsequent Phase II clinical trial?

A sponsor has successfully completed a Phase I trial for a new oncology drug, establishing its initial safety profile and identifying a maximum tolerated dose in healthy volunteers.
What is the primary objective of the subsequent Phase II clinical trial?